Q1 2026 · 13F-HR
Checkpoint Capital L.P.holdings as filed
Filed 2026-05-15 · accession 0001977548-26-000004
$278.7M
Reported value
8
Positions
2026-03-31
Period end
The Brief · Checkpoint Capital L.P. · Q1 2026
AI · grounded in 13F
Checkpoint Capital L.P. closed its position in Corcept Therapeutics Inc CORT, reducing its exposure by $18.4M. The fund established new positions in SEPTERNA INC ($2.4M), Crinetics Pharmaceuticals In CRNX ($1.4M), and Trevi Therapeutics Inc ($596.5K). Additionally, the fund increased its holdings in Rhythm Pharmaceuticals Inc RYTM by 23.6% and CytoKinetics Inc CYTK by 7.9%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04016X101 | ARGX | ARGENX SE | $111.7M | 40.1% | 153,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $106.7M | 38.3% | 1,227,200 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $25.5M | 9.16% | 262,539 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $18.3M | 6.58% | 286,661 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $11.9M | 4.26% | 180,000 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $2.4M | 0.86% | 100,300 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $1.5M | 0.52% | 40,230 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $596,500 | 0.21% | 50,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.